Caplin Point Laboratories gains as its arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Caplin Point Laboratories is currently trading at Rs. 1283.80, up by 23.85 points or 1.89 % from its previous closing of Rs. 1259.95 on the BSE.
The scrip opened at Rs. 1289.90 and has touched a high and low of Rs. 1302.35 and Rs. 1259.45 respectively. So far 4701 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1617.80 on 19-Feb-2024 and a 52 week low of Rs. 575.00 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1302.35 and Rs. 1240.00 respectively. The current market cap of the company is Rs. 9648.78 crore.
The promoters holding in the company stood at 70.62 % while Institutions and Non-Institutions held 3.26 % and 26.10 % respectively.
Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), a generic therapeutic equivalent version of (RLD), ACULAR Ophthalmic Solution of Allergan Inc.
Ketorolac tromethamine Ophthalmic Solution 0.5% is a nonsteroidal, anti- inflammatory indicated for the treatment of inflammation following cataract surgery and for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. According to IQVIATM (IMS Health), Ketorolac tromethamine Ophthalmic Solution 0.5% had US sales of around $36 million for the 12-month period ending December 2023.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
